Literature DB >> 17304447

Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome.

Jörg J Ruhe1, Nathaniel Smith, Robert W Bradsher, Anupama Menon.   

Abstract

BACKGROUND: Conflicting data exist on the role of antimicrobial therapy for the treatment of uncomplicated community-onset methicillin-resistant Staphylococcus aureus (MRSA) skin and soft-tissue infections (SSTIs).
METHODS: We performed a retrospective cohort study of 492 adult patients with 531 independent episodes of community-onset MRSA SSTIs, which consisted of abscesses, furuncles/carbuncles, and cellulitis, at 2 tertiary care medical centers. The purpose of the study was to determine the impact of active antimicrobial therapy (i.e., the use of an agent to which the organism is susceptible) and other potential risk factors on the outcome for patients with uncomplicated community-onset MRSA SSTIs. Treatment failure was the primary outcome of interest and was defined as worsening signs of infection associated with microbiological and/or therapeutic indicators of an unsuccessful outcome. Bivariate analyses and logistic regression analyses were preformed to determine predictors of treatment failure.
RESULTS: An incision and drainage procedure was performed for the majority of patients. Treatment failure occurred in 45 (8%) of 531 episodes of community-onset MRSA SSTI. Therapy was successful for 296 (95%) of 312 patients who received an active antibiotic, compared with 190 (87%) of 219 of those who did not (P=.001 in bivariate analysis). Use of an inactive antimicrobial agent was an independent predictor of treatment failure on logistic regression analysis (adjusted odds ratio, 2.80; 95% confidence interval, 1.26-6.22; P=.01).
CONCLUSIONS: Our findings suggest that certain patients with SSTIs that are likely caused by MRSA would benefit from treatment with an antimicrobial agent with activity against this organism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17304447     DOI: 10.1086/511872

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  48 in total

1.  Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  Jose Cadena; Shalini Nair; Andres F Henao-Martinez; James H Jorgensen; Jan E Patterson; Pranavi V Sreeramoju
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 2.  Antibacterials as adjuncts to incision and drainage for adults with purulent methicillin-resistant Staphylococcus aureus (MRSA) skin infections.

Authors:  Nicolas A Forcade; Nathan P Wiederhold; Laurajo Ryan; Robert L Talbert; Christopher R Frei
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

3.  Community acquired MRSA in Europe.

Authors:  Tristan Ferry; Jerome Etienne
Journal:  BMJ       Date:  2007-10-23

4.  Methicillin-resistant Staphylococcus aureus: from the hospital to the community.

Authors:  Armando Paez; Daniel Skiest
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

5.  Community-Acquired Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections: Management and Prevention.

Authors:  Luke F Chen; Cody Chastain; Deverick J Anderson
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

Review 6.  Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure.

Authors:  Abraham Pulido-Cejudo; Mario Guzmán-Gutierrez; Abel Jalife-Montaño; Alejandro Ortiz-Covarrubias; Jose Luis Martínez-Ordaz; Héctor Faustino Noyola-Villalobos; Luis Mauricio Hurtado-López
Journal:  Ther Adv Infect Dis       Date:  2017-08-31

7.  Community-Associated Methicillin-Resistant Staphylococcus aureus in the Pediatric Population.

Authors:  Carrie W Nemerovski; Kristin C Klein
Journal:  J Pediatr Pharmacol Ther       Date:  2008-10

8.  Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  Jörg J Ruhe; Anupama Menon
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

9.  Community-associated methicillin-resistant Staphylococcus aureus: trends in case and isolate characteristics from six years of prospective surveillance.

Authors:  Kathryn Como-Sabetti; Kathleen H Harriman; Jessica M Buck; Anita Glennen; David J Boxrud; Ruth Lynfield
Journal:  Public Health Rep       Date:  2009 May-Jun       Impact factor: 2.792

10.  Methicillin-susceptible, non-multiresistant methicillin-resistant and multiresistant methicillin-resistant Staphylococcus aureus infections: a clinical, epidemiological and microbiological comparative study.

Authors:  W J Munckhof; G R Nimmo; J Carney; J M Schooneveldt; F Huygens; J Inman-Bamber; E Tong; A Morton; P Giffard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-16       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.